MX2007015958A - Composiciones de peptido lkktet y/o lkktnt, y metodos. - Google Patents

Composiciones de peptido lkktet y/o lkktnt, y metodos.

Info

Publication number
MX2007015958A
MX2007015958A MX2007015958A MX2007015958A MX2007015958A MX 2007015958 A MX2007015958 A MX 2007015958A MX 2007015958 A MX2007015958 A MX 2007015958A MX 2007015958 A MX2007015958 A MX 2007015958A MX 2007015958 A MX2007015958 A MX 2007015958A
Authority
MX
Mexico
Prior art keywords
agent
lkktet
lkktnt
composition
methods
Prior art date
Application number
MX2007015958A
Other languages
English (en)
Spanish (es)
Inventor
Allan L Goldstein
David Crockford
Gabriel Sosne
Ewald Hanna Ppel
Original Assignee
Regenerx Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals filed Critical Regenerx Biopharmaceuticals
Publication of MX2007015958A publication Critical patent/MX2007015958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2007015958A 2005-06-17 2006-06-19 Composiciones de peptido lkktet y/o lkktnt, y metodos. MX2007015958A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US77694706P 2006-02-28 2006-02-28
PCT/US2006/023760 WO2006138709A2 (en) 2005-06-17 2006-06-19 Lkktet and/or lkktnt peptide compositions and methods

Publications (1)

Publication Number Publication Date
MX2007015958A true MX2007015958A (es) 2008-04-17

Family

ID=37570786

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2007015958A MX2007015958A (es) 2005-06-17 2006-06-19 Composiciones de peptido lkktet y/o lkktnt, y metodos.
MX2007015957A MX2007015957A (es) 2005-06-17 2006-06-19 Composiciones de peptido lkktet y/o lkktnt que estan liofilizadas o en una forma capaz de ser liofilizada.
MX2007015956A MX2007015956A (es) 2005-06-17 2006-06-19 Composiciones de lkktet y/o lkktnt para tratar o prevenir el deterioro, lesion o dano a tejido.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2007015957A MX2007015957A (es) 2005-06-17 2006-06-19 Composiciones de peptido lkktet y/o lkktnt que estan liofilizadas o en una forma capaz de ser liofilizada.
MX2007015956A MX2007015956A (es) 2005-06-17 2006-06-19 Composiciones de lkktet y/o lkktnt para tratar o prevenir el deterioro, lesion o dano a tejido.

Country Status (11)

Country Link
US (8) US20090131313A1 (enExample)
EP (4) EP1896050A4 (enExample)
JP (3) JP2008543877A (enExample)
KR (3) KR20080033939A (enExample)
CN (1) CN105106931A (enExample)
AU (3) AU2006261155A1 (enExample)
CA (3) CA2612410A1 (enExample)
HK (1) HK1218248A1 (enExample)
IL (4) IL187522A0 (enExample)
MX (3) MX2007015958A (enExample)
WO (3) WO2006138707A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
EP2485765A2 (en) * 2009-10-09 2012-08-15 Board Of Regents The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
PL3065756T3 (pl) 2013-11-07 2019-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Stabilnie przechowywane liofilizowane formulacje tripeptydowe
US10302658B2 (en) 2014-03-12 2019-05-28 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
JP6634451B2 (ja) 2014-10-22 2020-01-22 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
US10744088B2 (en) 2015-10-06 2020-08-18 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
KR102488796B1 (ko) * 2016-07-18 2023-01-13 리젠트리 엘엘씨 안구 건조증 치료 방법
KR102115158B1 (ko) 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
US20190381136A1 (en) * 2017-02-21 2019-12-19 Tearsolutions, Inc. Stable peptide compositions
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
AU2018372396A1 (en) * 2017-11-24 2020-06-25 HLB Therapeutics Co., Ltd. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
WO2024006653A2 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
AU3070395A (en) * 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
WO2000006190A1 (en) * 1998-07-30 2000-02-10 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health THYMOSIN β4 PROMOTES WOUND REPAIR
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
AU2001292881A1 (en) * 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
EP1427432A4 (en) * 2001-08-29 2008-01-23 Regenerx Biopharmaceuticals METHOD FOR HEALING OR PREVENTING IGNITION, DAMAGE, AND OTHER CHANGES ARISING BEFORE, DURING, OR DIRECTLY TO A MYOKARDIN FARM, WITH THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
WO2003073911A2 (en) * 2002-02-28 2003-09-12 Georgetown University Method and composition for detection and treatment of breast cancer
PL374700A1 (pl) * 2002-09-20 2005-10-31 Alcon, Inc. Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
EP1613369A4 (en) * 2003-03-31 2008-10-01 Regenerx Biopharmaceuticals COMPOSITIONS AND METHODS OF DELIVERING THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
WO2017017553A1 (en) 2015-07-30 2017-02-02 Semiconductor Energy Laboratory Co., Ltd. Manufacturing method of light-emitting device, light-emitting device, module, and electronic device

Also Published As

Publication number Publication date
US20090118196A1 (en) 2009-05-07
AU2006261157A1 (en) 2006-12-28
US20180028619A1 (en) 2018-02-01
US9585941B2 (en) 2017-03-07
EP1896050A2 (en) 2008-03-12
US9821030B2 (en) 2017-11-21
EP1896050A4 (en) 2010-01-27
IL187781A (en) 2012-04-30
EP1906986A4 (en) 2011-02-23
WO2006138707A1 (en) 2006-12-28
EP1906986A1 (en) 2008-04-09
JP2008543878A (ja) 2008-12-04
JP2008543879A (ja) 2008-12-04
IL218504A0 (en) 2012-04-30
CA2612522A1 (en) 2006-12-28
CA2612410A1 (en) 2006-12-28
IL187781A0 (en) 2008-08-07
US20160287673A1 (en) 2016-10-06
KR20080021782A (ko) 2008-03-07
MX2007015956A (es) 2008-03-06
AU2006261156B2 (en) 2012-05-31
CA2612405A1 (en) 2006-12-28
US20170128540A1 (en) 2017-05-11
IL187522A0 (en) 2008-03-20
WO2006138708A1 (en) 2006-12-28
IL187617A0 (en) 2008-03-20
EP1904080A4 (en) 2011-02-16
US20080214456A1 (en) 2008-09-04
KR20080018268A (ko) 2008-02-27
WO2006138708B1 (en) 2007-04-05
EP3326647A1 (en) 2018-05-30
US10004785B2 (en) 2018-06-26
MX2007015957A (es) 2008-03-06
WO2006138709A3 (en) 2007-07-05
WO2006138709A2 (en) 2006-12-28
US20160193301A1 (en) 2016-07-07
JP2008543877A (ja) 2008-12-04
HK1218248A1 (zh) 2017-02-10
KR20080033939A (ko) 2008-04-17
IL218504A (en) 2013-10-31
US20120071411A1 (en) 2012-03-22
AU2006261155A1 (en) 2006-12-28
US8383576B2 (en) 2013-02-26
CN105106931A (zh) 2015-12-02
US20090131313A1 (en) 2009-05-21
AU2006261156A1 (en) 2006-12-28
EP1904080A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
MX2007015958A (es) Composiciones de peptido lkktet y/o lkktnt, y metodos.
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
UA100851C2 (ru) Средство для борьбы с паразитами на животных
EA200801406A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
MXPA05001727A (es) Composiciones y proceso para suministrar un aditivo.
EP3318128A3 (en) Composition comprising a biological control agent and a fungicide
MX2009008411A (es) Ectoparasiticida de accion prolongada con alta dosis para un control prolongado.
TW200644719A (en) OLEDs utilizing direct injection to the triplet state
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
EP2428222A3 (en) Vaccine peptide combinations against cat allergy
MY159156A (en) Antibody formulation
ZA201001054B (en) Peptide with reduced dimer formation
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
TW200700086A (en) Injectable non-aqueous suspension
TNSN07222A1 (en) Nematicidal compositions
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2008098169A3 (en) Compositions and methods including expression and bioactivity of bovine follicle stimulating hormone
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
TW200724159A (en) Stable emulsion composition
WO2010092014A3 (en) Pesticidal mixtures
EP1988915A4 (en) METHOD FOR MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREFROM
TW200640376A (en) Reduction of digestibility of phosphorus
UA90367C2 (ru) Зерна зерновых культур, обработанные водной композицией родентицида, способ приготовления композиции для приманки и способ борьбы с грызунами
UA98447C2 (ru) АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ
WO2010062057A3 (ko) 수정란의 착상 또는 임신 촉진용 조성물

Legal Events

Date Code Title Description
FA Abandonment or withdrawal